The U.S. Supreme Court’s recent decision to overturn the Chevron deference, a longstanding precedent that favored federal agencies’ rulemaking interpretations, is poised to prompt a series of legal challenges aimed at the U.S. Food and Drug Administration (FDA). Legal analysts suggest that key areas of scrutiny will include the extent of the FDA’s authority under the Federal Food, Drug, and Cosmetic Act. Attorneys from Debevoise highlight the potential for a wave of litigation addressing what some may view as FDA overreach.
For more detailed insights, the implications of this ruling are further elaborated by attorneys at Debevoise in their Law360 article.